Syon Capital LLC Purchases Shares of 26,573 Dynavax Technologies Co. (NASDAQ:DVAX)

Syon Capital LLC purchased a new stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 26,573 shares of the biopharmaceutical company's stock, valued at approximately $339,000.

Several other large investors have also modified their holdings of the company. E Fund Management Co. Ltd. boosted its holdings in shares of Dynavax Technologies by 4.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock valued at $225,000 after acquiring an additional 771 shares during the period. Summit Investment Advisors Inc. increased its stake in Dynavax Technologies by 7.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 904 shares during the period. Nisa Investment Advisors LLC raised its position in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Dynavax Technologies by 6.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 1,109 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. Finally, William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Price Performance

DVAX stock traded down $0.32 during trading on Thursday, reaching $11.44. 600,218 shares of the company were exchanged, compared to its average volume of 2,199,425. The company has a market cap of $1.40 billion, a P/E ratio of 63.46 and a beta of 1.26. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63. The stock's 50 day moving average price is $12.67 and its 200 day moving average price is $12.57. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts' consensus estimates of $0.05. The firm had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.